Ngā hua rapu - Emilio A. Emini

Whakamahine hua
  1. 1
    Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization

    Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization mā Emilio A. Emini, Philomena Ostapchuk, Eckard Wimmer

    I whakaputaina 1983
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C

    Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C mā S Pincus, David C. Diamond, Emilio A. Emini, Eckard Wimmer

    I whakaputaina 1986
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide

    Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide mā Emilio A. Emini, J V Hughes, Debra S. Perlow, Joshua Boger

    I whakaputaina 1985
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    A novel assay for the DNA strand-transfer reaction of HIV-1 integrase

    A novel assay for the DNA strand-transfer reaction of HIV-1 integrase mā Daria J. Hazuda, Jeffrey C. Hastings, Abigail Wolfe, Emilio A. Emini

    I whakaputaina 1994
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies

    Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies mā Emilio A. Emini, S Y Kao, Angela Lewis, R Crainic, Eckard Wimmer

    I whakaputaina 1983
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies

    Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies mā Emilio A. Emini, Bradford A. Jameson, Angela Lewis, G R Larsen, Eckard Wimmer

    I whakaputaina 1982
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy

    Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy mā Jon H. Condra, Christos J. Petropoulos, Rainer Ziermann, William A. Schleif, Malathi Shivaprakash, Emilio A. Emini

    I whakaputaina 2000
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

    Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody mā Miroslaw K. Górny, Alan J. Conley, S Karwowska, Aby Buchbinder, Jiake Xu, Emilio A. Emini, Scott Koenig, Susan Zolla‐Pazner

    I whakaputaina 1992
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

    Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. mā Alan J. Conley, Joseph Kessler, L J Boots, J S Tung, Beth Arnold, Paul M. Keller, Alan Shaw, Emilio A. Emini

    I whakaputaina 1994
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors

    Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors mā Jon H. Condra, Emilio A. Emini, L Gotlib, Donald J. Graham, A J Schlabach, Jill Wolfgang, Richard J. Colonno, Vinod Sardana

    I whakaputaina 1992
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Active human immunodeficiency virus protease is required for viral infectivity.

    Active human immunodeficiency virus protease is required for viral infectivity. mā Nancy E. Kohl, Emilio A. Emini, William A. Schleif, Lenora J. Davis, Jill C. Heimbach, Richard A. Dixon, Edward M. Scolnick, Irving S. Sigal

    I whakaputaina 1988
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.

    Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. mā Vinod Sardana, Emilio A. Emini, L Gotlib, Donald J. Graham, D W Lineberger, William J. Long, A J Schlabach, Jill Wolfgang, Jon H. Condra

    I whakaputaina 1992
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure

    Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure mā Joseph K. Wong, Huldrych F. Günthard, Diane V. Havlir, Zhi‐Qiang Zhang, Ashley T. Haase, Caroline Ignacio, Shirley Kwok, Emilio A. Emini, Douglas D. Richman

    I whakaputaina 1997
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

    Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors mā Jack H. Nunberg, William A. Schleif, Evelyn Boots, J A O'Brien, J C Quintero, J. M. HOFFMAN, Emilio A. Emini, Mark E. Goldman

    I whakaputaina 1991
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells

    Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells mā Robert L. LaFemina, Christine L. Schneider, Helen L. Robbins, P L Callahan, K LeGrow, E. Jill Roth, William A. Schleif, Emilio A. Emini

    I whakaputaina 1992
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

    Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada mā Otto G. Vanderkooi, David W. Scheifele, Douglas Girgenti, Scott A. Halperin, Scott D. Patterson, William C. Gruber, Emilio A. Emini, Daniel A. Scott, James D. Kellner

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

    Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees mā Emilio A. Emini, Peter L. Nara, William A. Schleif, John A. Lewis, J P Davide, D R Lee, Joseph Kessler, S Conley, Shuzo Matsushita, Scott D. Putney

    I whakaputaina 1990
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

    Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D mā Alan J. Conley, Miroslaw K. Górny, Joseph Kessler, L J Boots, M Ossorio-Castro, Scott Koenig, D W Lineberger, Emilio A. Emini, Constance Williams, Susan Zolla‐Pazner

    I whakaputaina 1994
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine mā Lisa A. Jackson, Alejandra Gurtman, Kathryn Rice, Karlis Pauksens, Richard N. Greenberg, Thomas R. Jones, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmöele-Thoma

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults mā Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff, Kathrin U. Jansen, Deepthi Jayawardene, Carmel Devlin, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmöele-Thoma

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: